-
Potential Gene Therapy for Sickle Cell Named ‘Orphan Drug’ by FDA, Aruvant Announces
Orphan drug designation supports the development of ARU-1801, Aruvant’s gene therapy candidate for SCD that is now in a clinical trial in up to 10 patients. Read more about it here.
What did you think of this news?
Sorry, there were no replies found.
Log in to reply.